Niaprazine

• CAT Number: I033247
• CAS Number: 27367-90-4
• Molecular Formula: C20H25FN4O
• Molecular Weight: 356.45
• Purity: 98%
• Synonyms: Niaprazine
• Target: Neuronal Signaling
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N-(3-(4-(4-Fluorophenyl)-1-piperazinyl)-1-methylpropyl)-3-pyridinecarboxamide
• InChI: InChI=1S/C20H25FN4O/c1-16(23-20(26)17-3-2-9-22-15-17)8-10-24-11-13-25(14-12-24)19-6-4-18(21)5-7-19/h2-7,9,15-16H,8,10-14H2,1H3,(H,23,26)
• InChIKey: RSKQGBFMNPDPLR-UHFFFAOYSA-N
• SMILES: O=C(C1=CC=CN=C1)NC(C)CCN2CCN(C3=CC=C(F)C=C3)CC2

Niaprazine (Cat No.: I033247) is a sedative and antihistamine with selective H1 receptor antagonist properties, primarily used in neurological and sleep disorder research. It has mild hypnotic and anxiolytic effects, making it useful for studying pediatric insomnia, hyperactivity, and behavioral disorders. Niaprazine’s mechanism involves serotonin modulation, contributing to its calming effects without significant central nervous system depression. Its high safety profile and efficacy make it a valuable tool for exploring treatments for sleep disturbances, anxiety, and related neuropsychiatric conditions in research settings.

Reference

1: Keane PE, Strolin Benedetti M, Dow J. The effect of niaprazine on the turnover of 5-hydroxytryptamine in the rat brain. Neuropharmacology. 1982 Feb;21(2):163-9. doi: 10.1016/0028-3908(82)90157-5. PMID: 6460945.
2: Rossi PG, Posar A, Parmeggiani A, Pipitone E, D’Agata M. Niaprazine in the treatment of autistic disorder. J Child Neurol. 1999 Aug;14(8):547-50. doi: 10.1177/088307389901400814. PMID: 10456769.
3: Pisciotta L, Gherzi M, Stagnaro M, Calevo MG, Giannotta M, Vavassori MR, Veneselli E; I.B.AHC Consortium, De Grandis E. Alternating Hemiplegia of Childhood: Pharmacological treatment of 30 Italian patients. Brain Dev. 2017 Jun;39(6):521-528. doi: 10.1016/j.braindev.2017.02.001. Epub 2017 Feb 27. PMID: 28249736.
4: Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, Rumigny JF. Molecular pharmacology of niaprazine. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):989-1001. doi: 10.1016/0278-5846(88)90093-0. PMID: 2853885.
5: Niederhofer H. Niaprazine may improve some symptoms of attention-deficit hyperactivity disorder. Minerva Pediatr. 2010 Apr;62(2):231-2. PMID: 20440244.
6: Franzoni E, Masoni P, Mambelli M, Marzano P, Donati C. La niaprazina nei disturbi del comportamento del bambino. Confronto in doppio cieco contro placebo [Niaprazine in behavior disorders in children. Double-blind comparison with placebo]. Pediatr Med Chir. 1987 Mar-Apr;9(2):185-7. Italian. PMID: 2958783.
7: Keane PE, Benedetti MS. Niaprazine, a selective brain catecholamine depletor. Neuropharmacology. 1979 Jul;18(7):595-600. doi: 10.1016/0028-3908(79)90110-2. PMID: 158713.
8: Pozzi M, Conti V, Locatelli F, Galbiati S, Radice S, Clementi E, Strazzer S. Paroxysmal Sympathetic Hyperactivity in Pediatric Rehabilitation: Pathological Features and Scheduled Pharmacological Therapies. J Head Trauma Rehabil. 2017 Mar/Apr;32(2):117-124. doi: 10.1097/HTR.0000000000000255. PMID: 27603764.
9: Montanari G, Schiaulini P, Covre A, Steffan A, Furlanut M. Niaprazine vs chlordesmethyldiazepam in sleep disturbances in pediatric outpatients. Pharmacol Res. 1992 Feb-Mar;25 Suppl 1:83-4. doi: 10.1016/1043-6618(92)90551-l. PMID: 1354861.
10: Ottaviano S, Giannotti F, Cortesi F. The effect of niaprazine on some common sleep disorders in children. A double-blind clinical trial by means of continuous home-videorecorded sleep. Childs Nerv Syst. 1991 Oct;7(6):332-5. doi: 10.1007/BF00304832. PMID: 1837245.
11: Bodiou C, Bavoux F. Niaprazine et effets indésirables en pédiatrie. Bilan coopératif des centres français de pharmacovigilance [Niaprazine and side effects in pediatrics. Cooperative evaluation of French centers of pharmacovigilance]. Therapie. 1988 Jun-Jul;43(4):307-11. French. PMID: 2903572.
12: Sarda H, Benkhelifa S, Housset C, Le Loc’h H. Malaise après niaprazine (Nopron) [Syncope after niaprazine (Nopron)]. Arch Pediatr. 1996 Jan;3(1):90. French. doi: 10.1016/s0929-693x(96)80020-0. PMID: 8745837.
13: Duchene-Marullaz P, Rispat G, Perriere JP, Hache J, Labrid C. De quelques propriétés pharmacodynamiques de la niaprazine, nouvel antihistaminique [Some pharmacodynamical properties of niaprazine, a new antihistaminic agent]. Therapie. 1971 Nov-Dec;26(6):1203-9. French. PMID: 4401719.
14: Auduy B. Défaillance cardio-respiratoire aiguë après absorption de niaprazine [Acute cardio-respiratory failure after niaprazine absorption]. Arch Fr Pediatr. 1988 Jun-Jul;45(6):439. French. PMID: 2905885.
15: Veneselli E, Biancheri R. Alternating hemiplegia of childhood: treatment of attacks with chloral hydrate and niaprazine. Eur J Pediatr. 1997 Feb;156(2):157-8. PMID: 9039526.
16: Younus M, Labellarte MJ. Insomnia in children: when are hypnotics indicated? Paediatr Drugs. 2002;4(6):391-403. doi: 10.2165/00128072-200204060-00006. PMID: 12038875.
17: Lee W, Day TJ, Williams DR. Clinical, laboratory and electrophysiological features of Morvan’s fibrillary chorea. J Clin Neurosci. 2013 Sep;20(9):1246-9. doi: 10.1016/j.jocn.2012.10.029. Epub 2013 May 24. PMID: 23712055.
18: Dostert P, Strolin Benedetti M, Rovei V, Smith RL. Can a 1,2-oxygen shift of a nicotinamide N-oxide derivative occur in vivo? Xenobiotica. 1985 Oct;15(10):799-803. doi: 10.3109/00498258509045031. PMID: 2933883.
19: Mancini J, Thirion X, Masut A, Saillard C, Pradel V, Romain F, Pastor MJ, Coudert C, Micallef J. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol Drug Saf. 2006 Jul;15(7):494-503. doi: 10.1002/pds.1258. PMID: 16700077.
20: De Zen L, Del Rizzo I, Robazza M, Barbieri F, Campagna M, Vaccher S, Barbi E, Dall’Amico R. Home Use of Intranasal Dexmedetomidine in a Child With An Intractable Sleep Disorder. J Pediatr Pharmacol Ther. 2020;25(4):332-335. doi: 10.5863/1551-6776-25.4.332. PMID: 32461748; PMCID: PMC7243900.